This company listing is no longer active
Metacrine Past Earnings Performance
Past criteria checks 0/6
Metacrine's earnings have been declining at an average annual rate of -24.1%, while the Biotechs industry saw earnings growing at 32.7% annually. Revenues have been declining at an average rate of 107.1% per year.
Key information
-24.1%
Earnings growth rate
35.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -107.1% |
| Return on equity | -103.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Recent updates
Equillium acquires Metacrine to extend cash runway through 2024
Sep 06Metacrine initiated buy at H.C. Wainwright citing novelty in therapeutic platform
Jun 14Metacrine completes enrollment in mid-stage NASH trial
Jun 02Metacrine initiates mid-stage study of MET409 + empagliflozin in diabetes and NASH
Jan 05What Percentage Of Metacrine, Inc. (NASDAQ:MTCR) Shares Do Insiders Own?
Dec 16
Metacrine reports Q3 results
Nov 12Revenue & Expenses BreakdownBeta
How Metacrine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -38 | 17 | 0 |
| 30 Jun 22 | 0 | -51 | 17 | 0 |
| 31 Mar 22 | 0 | -60 | 17 | 0 |
| 31 Dec 21 | 0 | -62 | 16 | 0 |
| 30 Sep 21 | 0 | -59 | 16 | 0 |
| 30 Jun 21 | 0 | -50 | 14 | 0 |
| 31 Mar 21 | 0 | -44 | 12 | 0 |
| 31 Dec 20 | 0 | -37 | 10 | 0 |
| 30 Sep 20 | 0 | -34 | 7 | 0 |
| 30 Jun 20 | 0 | -33 | 5 | 0 |
| 31 Mar 20 | 0 | -31 | 5 | 0 |
| 31 Dec 19 | 0 | -29 | 4 | 0 |
| 31 Mar 19 | 1 | -28 | 6 | 0 |
| 31 Dec 18 | 1 | -26 | 5 | 0 |
| 31 Mar 18 | 2 | -14 | 2 | 0 |
| 31 Dec 17 | 1 | -12 | 2 | 0 |
Quality Earnings: MTCR is currently unprofitable.
Growing Profit Margin: MTCR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MTCR is unprofitable, and losses have increased over the past 5 years at a rate of 24.1% per year.
Accelerating Growth: Unable to compare MTCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTCR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
Return on Equity
High ROE: MTCR has a negative Return on Equity (-103.03%), as it is currently unprofitable.